Trending News

Labor Secretary Lifts Abeyance on OFCCP Disability and Veteran Matters

In Case You Missed It: DOL Prohibited From Collecting Liquidated Damages in Wage & Hour Pre-Litigation Investigations

SEC’s New Concept Release on Foreign Private Issuer Standards

What Regulated Businesses Should Know About the Supreme Court’s Recent NEPA Decision

NEW ATDS BATTLEGROUND: Texas Passes HUGE NEW AMENDMENT to Its State Telemarketing Law Reviving The Risk of Autodialer Cases

Supreme Court Eliminates Heightened Discrimination Standard Under Title VII

Cleaning the Cupboard—Six More Decisions in One Day, and a Largely Harmonious Court - SCOTUS Today

U.S. Supreme Court Holds Majority-Group Plaintiffs Are Not Subject to a Heightened Evidentiary Standard Under Title VII

Supreme Court Clarifies Title VII Evidentiary Standards in “Reverse Discrimination” Cases, Removing Heightened Standard

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies
Posted On Wednesday, July 02, 2025
SurgiBox Expands European Presence Through Strategic Partnership with Ondatec Medical in Türkiye
Posted On Wednesday, July 02, 2025
Cronos Grows its International Footprint in Switzerland
Posted On Wednesday, July 02, 2025
Highest THCa Flower July 2025: New Hemp Hop Strains Hit the Market
Posted On Wednesday, July 02, 2025
InFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) Code
Posted On Wednesday, July 02, 2025
Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval
Posted On Wednesday, July 02, 2025
Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc.
Posted On Wednesday, July 02, 2025
Pneumagen Announces Peer-Reviewed Publication of Positive Phase II Study Data Highlighting the Potential of Neumifil, a Novel Broad-Spectrum Antiviral
Posted On Wednesday, July 02, 2025
PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine
Posted On Wednesday, July 02, 2025
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
Posted On Wednesday, July 02, 2025
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
Posted On Wednesday, July 02, 2025
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Posted On Tuesday, July 01, 2025
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Posted On Tuesday, July 01, 2025
Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market
Posted On Tuesday, July 01, 2025
Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting
Posted On Tuesday, July 01, 2025
Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies
Posted On Tuesday, July 01, 2025
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
Posted On Tuesday, July 01, 2025
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Posted On Tuesday, July 01, 2025
ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
Posted On Tuesday, July 01, 2025
Dogecoin Cash Inc. (OTCQB: DOGP) Forms Dogecoin Treasury, Inc. to Support Development of Dogecoin-Related Tools and Infrastructure
Posted On Tuesday, July 01, 2025
BioNTX Expands 2025 Tech Transfer Showcase to Spotlight Regional Innovation and Collaboration
Posted On Tuesday, July 01, 2025
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
Posted On Tuesday, July 01, 2025
Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis
Posted On Tuesday, July 01, 2025
Processa Pharmaceuticals Provides Portfolio and Business Update
Posted On Tuesday, July 01, 2025
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right
Posted On Tuesday, July 01, 2025

Print